Cargando…

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

The objectives of this review were to collect and summarise evidence on therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases and to inform the EULAR Task Force for the formulation of evidence-based points to consider. A systematic literature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krieckaert, Charlotte, Hernández-Breijo, Borja, Gehin, Johanna Elin, le Mélédo, Guillaume, Balsa, Alejandro, Jani, Meghna, Mulleman, Denis, Navarro-Compan, Victoria, Wolbink, Gertjan, Isaacs, John D, van Tubergen, Astrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171282/ https://www.ncbi.nlm.nih.gov/pubmed/35980738 http://dx.doi.org/10.1136/rmdopen-2022-002216

Ejemplares similares

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participation
por: Butink, Maarten H P, et al.
Publicado: (2023)

Correction: Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
Publicado: (2022)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews
por: Rodriguez-García, Sebastián Cruz, et al.
Publicado: (2021)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

Eular Textbook on Rheumatic Diseases
por: Adwan, Marwan H.
Publicado: (2015)

Biosimilars: what do patients need to consider?
por: Skingle, Diana
Publicado: (2015)

Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
por: Bosch, Philipp, et al.
Publicado: (2021)

EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases
por: Najm, Aurélie, et al.
Publicado: (2019)

Effectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases
por: Marques, Andréa, et al.
Publicado: (2022)

Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
por: Burska, Agata, et al.
Publicado: (2023)

Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider
por: Ritschl, Valentin, et al.
Publicado: (2020)

Recommendations for the content and conduct of European League Against Rheumatism (EULAR) musculoskeletal ultrasound courses
por: Naredo, E, et al.
Publicado: (2008)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
por: Alunno, Alessia, et al.
Publicado: (2021)

Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2023)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology
por: Dejaco, Christian, et al.
Publicado: (2018)

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2022)

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
por: Dreesen, Erwin, et al.
Publicado: (2017)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Role of ultrasonography in the diagnosis of rheumatic diseases in light of ACR/EULAR guidelines
por: Płaza, Mateusz, et al.
Publicado: (2016)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives
por: Alunno, Alessia, et al.
Publicado: (2017)

Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis
por: Fernández-Fernández, Elisa, et al.
Publicado: (2022)

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (2020)

Adalimumab concentration-based tapering strategy: as good as the recommended dosage
por: Mulleman, Denis, et al.
Publicado: (2018)

Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study
por: Bogas, Patricia, et al.
Publicado: (2021)

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022)

Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases
por: Santos, Eduardo José Ferreira, et al.
Publicado: (2023)

EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
por: Mankia, Kulveer, et al.
Publicado: (2021)

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
por: van der Heijde, Désirée, et al.
Publicado: (2015)

EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative
por: van Onna, Marloes, et al.
Publicado: (2021)

Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands
por: Bos, Wouter H., et al.
Publicado: (2021)

Implementation of a hybrid healthcare model in rheumatic musculoskeletal diseases: 6-months results of the multicenter Digireuma study
por: Benavent, D., et al.
Publicado: (2023)

Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2022)

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs
por: Gwinnutt, James M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rre9st3smcbndbscl7qblsg94i